Clinical Trails

Early trial results from the AURORAS-1 and JYP0015M101 studies show that ERAS-0015, a new pan-RAS “molecular glue,” may be highly effective in treating solid tumors with KRAS G12X mutations, including lung and pancreatic cancers. In patients with non-small cell lung cancer, the drug achieved response rates of 62% in those receiving second-line or later treatment, […]

The COMPANION-002 trial tested Tovecimig (CTX-009) combined with paclitaxel in patients with advanced biliary tract cancer who had already received prior treatment. The combination worked better than paclitaxel alone, nearly doubling progression-free survival to 4.7 months compared with 2.6 months. Tumor response rates were also higher, with 17.1% of patients responding versus 5.3% in the

New early-stage trial results suggest that daraxonrasib (RMC-6236), a new targeted drug, may improve outcomes for patients with metastatic pancreatic cancer who have not yet received treatment. In two Phase 1/2 studies, daraxonrasib showed strong anti-tumor activity both alone and when combined with chemotherapy. Response rates reached 47% with the drug alone and 58% when

Results from the CAR-PRISM phase 2 trial show that the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) produced remarkable outcomes in patients with high-risk smoldering multiple myeloma, a precursor to active cancer. All 20 patients in the study responded to treatment, with most achieving deep remissions. Every patient became minimal residual disease (MRD) negative within two

A phase 2 clinical trial of the experimental drug elraglusib has shown promising results for patients with metastatic pancreatic cancer, according to research published in Nature Medicine. Patients who received elraglusib along with chemotherapy were twice as likely to be alive after one year compared to those who received chemotherapy alone, with survival rates of

The combination of darlifarnib with cabozantinib may overcome treatment resistance in advanced clear cell renal cell carcinoma. The study tested a “re-challenge” approach, where darlifarnib helps tumors respond again to cabozantinib, even in patients who had previously progressed on the same drug. This suggests a new way to extend the usefulness of existing therapies. In

Interim results show promising activity for rezatapopt (PC14586) in patients with advanced ovarian cancer carrying the TP53 Y220C mutation. Rezatapopt is a first-in-class oral drug designed to restore the function of the mutated p53 protein, a key tumor suppressor. By stabilizing this specific mutation, the drug helps cancer cells regain normal growth control, offering a

The EZH2 inhibitor mevrometostat is moving into phase 3 trials as a potential treatment for metastatic castration-resistant prostate cancer after encouraging early results. The approach targets EZH2, an epigenetic regulator that helps cancer cells become more aggressive and resistant to treatment, including androgen receptor pathway inhibitors like enzalutamide. In a phase 1 study, combining mevrometostat

A phase 1 trial suggests that the multipeptide T-cell activator iTAC-XS15-CLL could be a safe and promising immunotherapy for patients with chronic lymphocytic leukemia receiving BTK inhibitors. The study enrolled 20 patients with minimal residual disease who were in partial remission after treatment with ibrutinib, acalabrutinib, or zanubrutinib. Each patient received three doses of a

Partner Therapeutics has submitted a supplemental application to the U.S. Food and Drug Administration seeking approval of zenocutuzumab-zbco for adults with advanced or metastatic cholangiocarcinoma carrying NRG1 gene fusions. The National Comprehensive Cancer Network has already added the drug to its guidelines as a recommended option in biliary tract cancers. The submission is supported by